Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that keratinocyte growth factor is a potent mitogen in human hyperplastic prostate cells, suggesting it plays an important role in prostate growth by acting in a paracrine manner.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study found that vitamin D regulates cholesterol metabolism and may influence prostate cancer development through mechanisms affecting prostate cell growth and sex hormone metabolism.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This study found that severe obesity is positively associated with more severe lower urinary tract symptoms compared to moderate obesity in patients with prostatic enlargement.

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.

This study evaluated a new anti-baldness product, IPSTiC patch hair, designed to treat androgenetic alopecia, and reported that it effectively inhibits NO radical and 5α-reductase activity while maintaining safety and stability, suggesting its potential for topical use.

This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.

This study found that the non-steroidal antiandrogen RU58841 increased hair growth rates and promoted hair cycle initiation in balding human scalp grafts on testosterone-conditioned nude mice, indicating a positive effect on hair growth.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

This study found that early-onset male pattern baldness was associated with a reduced relative risk of prostate cancer.

Combining different treatments may be needed to effectively manage chronic prostatitis.

Dutasteride reduces DHT more effectively than finasteride.

In this study using Mendelian randomization analysis, researchers found no causal relationship between androgenic alopecia and prostate cancer risk, suggesting that previously observed associations in epidemiological studies might not be causal.

Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.

This study reports that finasteride can effectively treat androgenic alopecia and may reduce prostate cancer risk by 25% in men with risk factors.

In this animal study, finasteride exposure led to impaired spermatogenesis in rats, while the novel compound DA-9401, derived from three medicinal herbs, demonstrated potential in improving sperm parameters and reducing testicular apoptosis when used alone or with finasteride.

This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.

This study suggests that 5α-reduced glucocorticoids may have anti-inflammatory potential and could serve as biomarkers for liver inflammation in metabolic disease, with implications for drug development.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

Created microspheres show potential for safe and effective use in prostate artery embolization.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.

In this study, D-004 did not affect androgen-dependent development in rats exposed in utero, while finasteride caused significant changes in male offspring's androgen-dependent tissues.